Skip to main content
. 2018 Mar 19;8:4797. doi: 10.1038/s41598-018-23140-9

Figure 2.

Figure 2

Nanoprimer: towards therapeutic agent’s bioavailability optimization via a sequential administration. The accumulation of the nanoprimer in liver decreases the clearance of the therapeutic agent to obtain an increased efficacy for a same dose administered or to decrease the toxicity (and extra-cost of adverse events management or product loss) for a same efficacy.